UK study on mixing Covid vaccines between jabs to be expanded
April 14, 2021, 10:05 am

UK study on mixing Covid vaccines between jabs to be expanded

A healthcare worker prepares a dose of the Pfizer/BioNTech vaccine.

Researchers to examine whether mixing vaccines may give longer-lasting immunity against virus

A major UK study examining whether Covid vaccines can be safely mixed with different types of jabs for the first and second doses is to be expanded.

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford/AstraZeneca and Pfizer vaccines for the first and second doses, will now include a shot of the Moderna or Novavax vaccines.

The study is examining whether mixing vaccines may give broader, longer-lasting immunity against the virus and new variants, and offer more flexibility in the administration of vaccines.

Led by the University of Oxford, the study will seek to recruit adults aged over 50 who have received their first vaccination in the past eight to 12 weeks.

Matthew Snape, an associate professor in paediatrics and vaccinology at the University of Oxford, who is chief investigator on the trial, said: “The focus of both this and the original Com-Cov study is to explore whether the multiple Covid-19 vaccines that are available can be used more flexibly, with different vaccines being used for the first and second dose.

“If we can show that these mixed schedules generate an immune response that is as good as the standard schedules, and without a significant increase in the vaccine reactions, this will potentially allow more people to complete their Covid-19 immunisation course more rapidly.

“This would also create resilience within the system in the event of a shortfall in the availability of any of the vaccines in use.”

The volunteers, who will have received either the Oxford/AstraZeneca or Pfizer/BioNTech vaccine, will be randomly allocated to receive either the same vaccine for their second dose or a dose of the jabs produced by Moderna or Novavax.

The Moderna jab has started being rolled out across the UK, and the Novavax jab manufactured by GlaxoSmithKline (GSK) is under review by the Medicines and Healthcare products Regulatory Agency (MHRA).

The six new arms of the trial will each recruit 175 candidates, adding 1,050 recruits to the programme. The researchers will study any adverse reactions and the immune system responses to these new combinations of vaccines.

If the study shows promising results, the MHRA and Joint Committee on Vaccination and Immunisation (JCVI) would formally assess the safety and efficacy of any new vaccination regimen before it is rolled out to patients.

Snape said he hoped the results of the second part of the study would be available in June or July, with the first part expected to report results next month.

He told a press briefing: “What I’m hoping is that we won’t rule out any combinations. That’s how we need to look at it – are there any combinations we shouldn’t be giving because they don’t generate a good immune response, and I’m hoping that won’t be the case.

“And that will give us lots of flexibility, not just in the UK, not just in Europe where we’re looking about restricting uses of some vaccines for some age groups, but across the world, where we have, perhaps, a little bit more intermittent supply of vaccines, not as reliable.”

Prof Jeremy Brown, a member of the JCVI, said people would eventually have to mix Covid-19 jabs.

He told BBC Radio 4’s Today programme: “It’s practically going to have to be that way because, once you’ve completed a course of, say, the Moderna or Pfizer or the AstraZeneca with two doses, in the future it’s going to be quite difficult to guarantee you get the same type of vaccine again.”

source: Sarah Marsh

Levant

Nigel Boardman: from GQ list to chairing Greensill lobbying inquiry English universities despair as in-person teaching ruled out before 17 May

Upon arriving to participate in the summit of the European Political Community, which includes around forty heads of state in Budapest, he said, "I look forward to sitting with the elected U.S. president and seeing how we will collectively ensure we meet challenges, including the threats from Russia and North Korea." He also noted that the strengthening of ties between Russia and North Korea poses a threat to the United States as well, according to reports from Agence France-Presse.

Before Trump's victory, Rutte expressed confidence that a united Washington would remain part of the defensive alliance, even if Trump became the 47th president of the United States. In an interview with German public broadcaster ZDF last Monday night, he stated that both Republicans and Democrats understand that NATO serves not only the security of Europe but also that of America. He added that both candidates are aware that the security of the United States is closely tied to NATO.

On Wednesday, NATO congratulated Trump on his victory but did not address the Ukrainian issue.

It is noteworthy that the relationship between the elected U.S. president and the defense alliance was not the best during his first term in the White House. Trump criticized NATO member states multiple times and even hinted at withdrawing from the alliance unless they increased their financial contributions.

Additionally, the issue of the Russian-Ukrainian war is one of the matters that complicate relations between the two sides, especially since Trump has repeatedly stated that he can end this ongoing conflict, which began in 2022, quickly. He implied that he had a peace plan between Kyiv and Moscow, while his vice president, JD Vance, revealed aspects of that plan, which stipulated Ukraine's commitment not to join NATO, thereby sending reassuring signals to the Russians.

Furthermore, many NATO member states in Europe fear that Trump might halt military aid to Ukraine after he previously criticized the U.S. for pouring funds into supporting Ukrainian President Volodymyr Zelensky.